EVMN Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 7.47%, SMA50 28.22%, SMA200 30.82%). The stock’s 14-day RSI is 54.91 (neutral), while the ATR of 3.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.79% below its high and over 91.79% above its low. Average 10-day trading volume of 2.74 million shares is significantly above the 3-month average of 714.55 thousand, indicating heightened recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $65.00 to $26.00. The high target offers 390.57% upside. The low target suggests 96.23% downside. The mean target is $44.77. This offers 237.89% upside. Evommune, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by -22.89%. The prior quarter beat by 74.39%. Over the last six quarters, Apple has recorded several small beats. These include -5.02% in December 03, 2025.

Evommune, Inc. (NYSE:EVMN) closed at $13.25 USD, losing -$0.09 (-0.67%) from the previous close of $13.34. The stock is currently mid-range between its 52-week high and low $12.07 and $33.20. With a market capitalization of about $187.68 million, Evommune, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.86). Key stats such as the average daily volume over the past year has been around 690.77 thousand shares, trading with heavier-than-usual volume. Headquartered in Palo Alto, CA, Evommune, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Luis C. Pena, the company employs approximately 48 people and listed since November 06, 2025. Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions.

Evommune, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$24.35. This means the shares are trading below this model’s fair value.

Evommune, Inc. trades at a P/E ratio of -5.63, slightly below the S&P 500 average, with a price-to-sales ratio of 19.06 and a price-to-book ratio of 1.49 suggesting the stock is closer to book value. The P/FCF stands at -2.37, also above market averages.

Our AI price prediction model suggests that Evommune, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.98%, with price expected at $11.53 by July 22, 2026, within a range of $8.09 to $15.12 3-Month Outlook: Projected rise of 148.3%, reaching $32.90 by October 06, 2026, with a range of $32.23 to $33.64. 1-Year Outlook: Projected gain of 207.47%, with price at $40.74 by July 08, 2027, within a range of $40.28 to $41.28.

Evommune, Inc. (NYSE:EVMN) shares are flat 7.48% year-to-date currently trading near 52-week highs band. Valuation shows Evommune, Inc. trading at a premium to the broader market with a P/E of -5.63. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $44.77, suggesting 237.89% upside. Our AI forecast model points to short-term weakness (-12.98% over two weeks), a medium-term rise (148.3% over three months), and a longer-term gain (207.47% over one year), with expected trading ranges indicating moderate volatility.